Advertisement
Screener

XERIS BIOPHARMA HOLDINGS, INC. (XERS) Foreign Pre-Tax Income

2.8 / 5 stars · 68/120 Roast Me

XERIS BIOPHARMA HOLDINGS, INC. Foreign Pre-Tax Income

XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Foreign Pre-Tax Income of $46.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-03-02

  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was $46.46M, a 118.08% increase from fiscal 2024.
  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was $21.30M, a 467.05% increase from fiscal 2023.
  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was $3.76M.
  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2022 was -$19.00M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Foreign 12 month
2025-12-31$46.46M
10-K · filed 2026-03-02
2024-12-31$21.30M
10-K · filed 2026-03-02
2023-12-31$3.76M
10-K · filed 2026-03-02
2022-12-31-$19.00M
10-K · filed 2025-03-06
2021-12-31-$7.99M
10-K · filed 2024-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Innoviva, Inc. (INVA)United States$1.493B4.62
Xencor Inc (XNCR)United States$1.776B-7.33
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Septerna, Inc. (SEPN)United States$1.783B-63.01